Trial Profile
A prospective and retrospective multicenter cohort study of Daclatasvir + Asunaprevir combination therapy for chronic hepatitis C with and without liver cirrhosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2022
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SMART-C V3
- 09 Jun 2016 Status changed from not yet recruiting to recruiting.
- 13 Mar 2015 New trial record